Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $19.4 million.

  • Arrowhead Pharmaceuticals' Share-based Compensation rose 2736.54% to $19.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $67.5 million, marking a year-over-year decrease of 281.36%. This contributed to the annual value of $63.4 million for FY2025, which is 1433.32% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Share-based Compensation stood at $19.4 million for Q4 2025, which was up 2736.54% from $19.1 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Share-based Compensation's 5-year high stood at $34.6 million during Q3 2021, with a 5-year trough of $13.0 million in Q2 2025.
  • For the 5-year period, Arrowhead Pharmaceuticals' Share-based Compensation averaged around $21.2 million, with its median value being $19.4 million (2022).
  • In the last 5 years, Arrowhead Pharmaceuticals' Share-based Compensation soared by 20088.41% in 2021 and then plummeted by 4026.06% in 2023.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Share-based Compensation stood at $24.5 million in 2021, then dropped by 20.87% to $19.4 million in 2022, then grew by 1.57% to $19.7 million in 2023, then decreased by 22.77% to $15.2 million in 2024, then rose by 27.37% to $19.4 million in 2025.
  • Its Share-based Compensation stands at $19.4 million for Q4 2025, versus $19.1 million for Q3 2025 and $13.0 million for Q2 2025.